April 24, 2011

Use of Aspirin Associates with Longer Primary Patency of Hemodialysis Grafts

.   .   

This study was designed to assess the contribution of ASA alone after the recently published trial that showed extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts.  The results show that aspirin use caused a trend toward longer primary patency, but was not associated with prolongation of graft patency or patient survival.

Related Articles:

Vascular Access

Comments are closed.